Is Jenburkt Pharma overvalued or undervalued?

As of 4 July 2025, Jenburkt Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently deemed overvalued. Key ratios include a PE ratio of 18.96, an EV to EBITDA of 14.49, and a PEG ratio of 0.82, which suggest that while the growth prospects may be appealing, the current price does not adequately reflect the underlying value.
In comparison to its peers, Jenburkt Pharma's valuation stands out. For instance, Sun Pharma has a PE ratio of 35.2, while Cipla is considered attractive with a PE of 23.2. This highlights that Jenburkt Pharma, despite being classified as very expensive, has a relatively lower PE ratio compared to some peers, yet still appears overvalued in the broader context. Notably, the company's stock has outperformed the Sensex over the past year with a return of 56.85% compared to the Sensex's 4.23%, further complicating the valuation narrative.